In summary, our study demonstrated that the STAU2‐PALLD axis promoted the progression and metastasis of pancreatic cancer, and developed STAU2‐ASO as the first inhibitor targeting STAU2‐PALLD axis. This evidence concerns the gene STAU2 and pancreatic neoplasm.